MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
6.11
-0.04
-0.65%
After Hours: 6.11 0 0.00% 16:10 03/13 EDT
OPEN
6.13
PREV CLOSE
6.15
HIGH
6.34
LOW
5.96
VOLUME
87.82K
TURNOVER
--
52 WEEK HIGH
9.82
52 WEEK LOW
3.280
MARKET CAP
97.70M
P/E (TTM)
-3.6389
1D
5D
1M
3M
1Y
5Y
1D
Verrica Pharma Q4 And FY25 Revenue Improves; Plans Second Phase 3 Program For VP-102 In Mid 2026
NASDAQ · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)
TipRanks · 2d ago
Verrica Pharmaceuticals: Focused Ycanth Rollout and Underpenetrated Pediatric Market Drive Attractive Risk‑Reward and Support Buy Rating
TipRanks · 2d ago
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand
Reuters · 2d ago
Verrica Pharmaceuticals Non-GAAP EPS of -$1.24 misses by $0.82, revenue of $35.58M beats by $0.58M
Seeking Alpha · 2d ago
Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)
TipRanks · 2d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2d ago
Verrica FY 2025 total revenue rose 370% to USD 35.58 million as net loss narrowed 77% to USD 17.89 million
Reuters · 2d ago
More
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.